Analysts expect that Charles River Laboratories International, Inc. (NYSE:CRL) will announce sales of $456.18 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for Charles River Laboratories International’s earnings. The lowest sales estimate is $450.80 million and the highest is $461.00 million. Charles River Laboratories International reported sales of $425.72 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 7.2%. The firm is expected to report its next quarterly earnings results on Wednesday, November 1st.

According to Zacks, analysts expect that Charles River Laboratories International will report full year sales of $456.18 million for the current year, with estimates ranging from $1.82 billion to $1.83 billion. For the next fiscal year, analysts forecast that the firm will report sales of $1.96 billion per share, with estimates ranging from $1.93 billion to $1.98 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The company had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. During the same period in the previous year, the company earned $1.20 EPS. The business’s quarterly revenue was up 8.1% compared to the same quarter last year.

A number of research firms have recently weighed in on CRL. BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Barclays PLC restated a “hold” rating and set a $102.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 19th. Jefferies Group LLC restated a “buy” rating and set a $121.00 price target on shares of Charles River Laboratories International in a report on Friday, June 30th. Finally, Citigroup Inc. restated a “neutral” rating and set a $104.00 price target (up previously from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $97.06.

In related news, Director George Massaro sold 3,830 shares of the firm’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $100.81, for a total value of $386,102.30. Following the transaction, the director now directly owns 18,731 shares in the company, valued at approximately $1,888,272.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman James C. Foster sold 9,516 shares of the firm’s stock in a transaction on Monday, July 10th. The shares were sold at an average price of $98.92, for a total transaction of $941,322.72. Following the completion of the transaction, the chairman now owns 361,171 shares in the company, valued at $35,727,035.32. The disclosure for this sale can be found here. Insiders sold a total of 80,499 shares of company stock worth $7,946,191 over the last quarter. 2.20% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock worth $345,915,000 after buying an additional 3,815,298 shares during the last quarter. FMR LLC raised its stake in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares in the last quarter. Ariel Investments LLC raised its stake in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after buying an additional 483,564 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in Charles River Laboratories International during the first quarter valued at about $39,355,000. Finally, Marshall Wace North America L.P. bought a new stake in Charles River Laboratories International during the first quarter valued at about $39,355,000. Institutional investors and hedge funds own 95.81% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Charles River Laboratories International, Inc. (CRL) Will Post Quarterly Sales of $456.18 Million” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/10/analysts-anticipate-charles-river-laboratories-international-inc-crl-will-post-quarterly-sales-of-456-18-million.html.

Shares of Charles River Laboratories International (NYSE:CRL) opened at 98.36 on Thursday. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $102.32. The stock has a market capitalization of $4.69 billion, a PE ratio of 28.79 and a beta of 1.02. The stock’s 50 day moving average is $99.95 and its 200 day moving average is $91.50.

Charles River Laboratories International declared that its board has initiated a share repurchase plan on Wednesday, May 10th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.